Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-06-11
2009-11-03
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
07612039
ABSTRACT:
The growth of normal and abnormally proliferating cells can be inhibited by the introduction of agnoprotein, or biologically active fragments or derivatives of agnoprotein, into the cell in the absence of any other polyoma virus protein or viral replication.
REFERENCES:
patent: 5643567 (1997-07-01), Hung et al.
patent: 5801029 (1998-09-01), McCormick
patent: 5814315 (1998-09-01), Hung et al.
patent: 6197754 (2001-03-01), Hung et al.
patent: 6296845 (2001-10-01), Sampson-Johannes et al.
patent: 2001/0006633 (2001-07-01), Kirn
patent: 2001/0048920 (2001-12-01), Lee et al.
Skolnick et al. (Trends in Biotech., 18(1):34-39, 2000).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Verma et al. (Nature 1997, 389: 239-242).
Amalfitano et al. (Current Gene Therapy 2002, 2: 111-133).
Department of Health and Human Services has released a memorandum dated Jan. 14, 2003.
Pandha et al. (Current Opinion in Investigational Drugs 2000; 1 (1): 122-134).
Jay et al nature vol. 291 p. 346 (1981).
Zhao et al., “Effect of As2O3on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status,”Int'l J. Oncol. 21: 49-55 (2002).
Yoshida et al., “In vitro inhibition of cell proliferation, viability, and invasiveness in U87MG human glioblastoma cells by estramustine phosphate,”Neurosurgery39: 360-66 (1996).
Richard J. Frisque et al., “Human Polyomavirus JC Virus Genome”,Journal of Virology, vol. 51, No. 2, pp. 458-469 (1984).
DeValle L et al. (Feb. 11, 2002), “Expression of Human Neurotropic Polyomavirus JCV Late Gene Product Agnoprotein in Human Medullablastoma,”J. Nat. Cancer Inst. 94(4).
Cubitt CL et al. (2001), “Predicted Amino Acid Sequences for 100 JCV Strains,”J Neurovirol., 7(4): 339-344.
Jobes DV et al. (1999), “A Novel JC Virus Variant Found in the Highlands of Papua New Guinea Has a 21-Base Pair Deletion in the Agnoprotein Gene,”J. Hum. Virol. 2(6): 350-358.
Safak M et al. (2001), “Interaction of JC Virus Agno Protein with T Antigen Modulates Transcription and Replication of the Viral Genome in Glial Cells,”J. Virol. 75(3): 1476-1486.
Stacy T et al. (1989), “Simian Virus 40 Host Range/Helper Function Mutations Cause Multiple Defects in Viral Late Gene Expression,”J. Virol. 63(12): 5208-5215.
Khalili K et al. (1988), “Carboxyl-terminal mutants of the large tumor antigen of simian virus 40: A role for the early protein late in the lytic cycle,”Proc. Natl. Acad. Sci. USA85: 354-358.
Resnick J and Shenk T (1986), “Simian Virus 40 Agnoprotein Facilitates Normal Nuclear Location of the Major Capsid Polypeptide and Cell-to-Cell Spread of Virus,”J. Virol. 60(3): 1098-1106.
Carswell S and Alwine J, “Simian Virus 40 Agnoprotein Facilitates Perinuclear-Nuclear Localization of VP1, the Major Capsid Protein,”J. Virol. 60(3): 1055-1061, 1986.
Hay N and Aloni Y (1985), “Attenuation of Late Simian Virus 40 mRNA Synthesis Is Enhance by the Agnoprotein and Is Temporally Regulated in Isolated Nuclear Systems,”Mol. and Cell. Biol.5(6): 1327-1334.
Nomura S et al (1983), “Subcellular Localization of the Simian Virus 40 Agnoprotein,”J. Virol. 45(1): 428-433.
Alwine JC (1982), “Evidence for Simian Virus 40 Late Transcriptional Control: Mixed Infections of Wild-Type Simian Virus 40 and a Late Leader Deletion Mutant ExhibittransEffects on Late Viral RNA Synthesis,”J. Virol. 42(3): 798-803.
Hay N et al. (1982), “Attenuation in the Control of SV40 Gene Expression,”Cell. 29: 183-193.
Drinker Biddle & Reath LLP
Huff Sheela J
Monaco Daniel A.
Temple University - Of The Commonwealth System of Higher Educati
LandOfFree
Method of cell growth inhibition with agnoprotein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of cell growth inhibition with agnoprotein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of cell growth inhibition with agnoprotein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4083915